Delayed GN Hearing device sent for FDA evaluation

Hearing device Jabra Enhance Plus, which GN Hearing is hoping will open up a new market, has been submitted to the US Food and Drug Administration for assessment. Earlier this month, product launch delays led to the head of reasearch and development being let go.

Photo: GN Hearing / PR

The launch of the new hearing device Jabra Enhance Plus, which is developed by GN Hearing, now depends on the US Food and Drug Administration (FDA), as the company has sent the product off for evaluation, CEO Gitte Aabo tells MedWatch in an interview.

Earlier this month, GN had to acknowledge that certain product milestones hadn't been reached, and thus a 2021 launch was no longer on the table. Consequently, the hearing aid manufacturer downgraded its financial guidance for the year, and let its former Head of Research and Development Pär Thureson go.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Rumored GN purchase unlikely but not impossible, say analysts

A low value assessment, a high structural value, and no dominant shareholders make GN Group a reasonable investment case for international private equity firms and industrial players. But just how likely is it? Analysts reveal their best bets for what a GN acquisition could look like.

New CFO wants to shake things up at WSA

A mere month into her new job, Marianne Wiinholt, WS Audiology’s fifth chief financial officer since the firm was established through a merger in 2019, is heralding great structural changes.

Further reading

Related articles

Latest news

See all jobs